These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Adjuvant immunotherapy for melanoma. Thomas D; Bello DM J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889 [TBL] [Abstract][Full Text] [Related]
12. Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanoma. Czarnecka AM; Ostaszewski K; Błoński P; Szumera-Ciećkiewicz A; Kozak K; Placzke J; Borkowska A; Terlecka A; Rogala P; Świtaj T; Sałamacha M; Mitręga-Korab B; Krotewicz M; Dudzisz-Śledź M; Rutkowski P Eur J Surg Oncol; 2024 Jul; 50(7):108382. PubMed ID: 38763112 [TBL] [Abstract][Full Text] [Related]
13. [Managing cutaneous melanoma]. Thomas L; Cochran AJ Cancer Radiother; 1998 Dec; 2(6):732-46. PubMed ID: 9922781 [TBL] [Abstract][Full Text] [Related]
14. News from the melanoma sessions of the European Cancer Congress 2017. Rutkowski P; Kozak K BMC Med; 2017 Mar; 15(1):57. PubMed ID: 28302128 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. Long GV; Menzies AM; Scolyer RA J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746 [TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. McKean MA; Amaria RN Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]